The Oncologist: Updates from the phase III MONALEESA trials, which evaluated ribociclib plus endocrine therapy in patients with HR-positive, HER2-negative advanced breast cancer, focused on treatment outcomes across subgroups. This evidence concerns the gene ERBB2 and breast cancer.